Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Milk thistle and liver disease

This article was originally published in The Tan Sheet

Executive Summary

Insufficient evidence in literature review precludes recommendation of herbal for acute and chronic liver disease, Bradly Jacobs, MD, et al., Osher Center for Integrative Medicine, UCSF, conclude. With mortality or biochemical markers as outcomes, researchers discerned no significant difference between milk thistle and placebo. Fourteen trials were selected from 13 databases and interviews with manufacturers and experts, comprising research dating from January 1966 through July 1999. The ingredient, however, is safe and well tolerated, say the researchers, who looked at 18 AERs. Larger clinical trials should be conducted to further study efficacy, Jacobs et al. propose

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel